Form 4: DexCom Director Sells Shares Under Pre-Arranged Trading Plan

DexCom Inc. Director Mark G. Foletta sold 2,750 shares of common stock through a pre-arranged 10b5-1 trading plan.

Summary

• Mark G. Foletta, a Director of DexCom Inc. (DXCM), sold a total of 2,750 shares of common stock on July 15, 2025.
• One transaction involved the sale of 2,742 shares at a weighted average price of $85.1672 per share.
• Another transaction involved the sale of 8 shares at a price of $86.03 per share.
• The sale of 2,742 shares was executed pursuant to a Rule 10b5-1 trading plan adopted by The Foletta Family Trust DTD 1/30/2015 on March 13, 2025, designed for the orderly disposition of shares.
• Following these transactions, Mark G. Foletta beneficially owns 53,871 shares indirectly through The Foletta Family Trust.
• Additionally, Mark G. Foletta directly holds 5,731 unvested restricted stock units (RSUs) granted on May 8, 2025.

Sentiment

Score: 5

Explanation: The sale of shares by a director is generally neutral to slightly negative, but the fact that it was conducted under a pre-arranged 10b5-1 plan mitigates any strong negative sentiment, as it suggests a planned disposition rather than a reaction to new, adverse information.

Positives

• The sale of 2,742 shares was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a structured and orderly disposition of shares rather than a reaction to immediate market conditions.

Negatives

• An insider, who is a Director, reduced their beneficial ownership of common stock by selling 2,750 shares.

Future Outlook

The unvested restricted stock units (RSUs) granted on May 8, 2025, are scheduled to vest on the earlier of the one-year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.

Industry Context

This filing details an individual insider transaction and does not provide broader insights into industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale by a director, even if pre-planned, slightly reduces insider ownership, which some investors may view as a minor negative, though the impact is likely minimal given the small percentage of total shares outstanding.

Next Steps

• Vesting of 5,731 unvested restricted stock units on the earlier of May 8, 2026, or DexCom, Inc.'s 2026 Annual Meeting of Stockholders.

Key Dates

Keywords

DexCom, DXCM, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Director, Common Stock, Restricted Stock Units